A n increasing number of studies have demonstrated that cardiovascular disease is the primary cause of morbidity and mortality in chronic kidney disease (CKD). 1 The increased incidence of cardiovascular events in patients with CKD is related to both traditional and nontraditional cardiovascular risk factors. 2 Nontraditional cardiovascular risk factors include uremia-related factors, inflammation, and abnormal metabolism of calcium and phosphate. 3, 4 Extracellular fluid (ECF) excess is a common condition in patients with advanced CKD and undergoing dialysis, and previous studies have shown that ECF excess is associated with all-cause mortality and cardiovascular morbidity. 5, 6 Although there is abundant evidence that ECF status is associated with adverse clinical outcomes in patients undergoing dialysis, only a few studies have evaluated the association of fluid excess with cardiovascular risk factors or adverse cardiovascular outcomes in patients with CKD.
The clinical assessment of ECF status is relatively difficult because the physical signs of edema are of limited value in diagnosing excess intravascular volume and tissue hydration status. 7, 8 Bioelectrical impedance analysis (BIA) is a method of assessing ECF status by measuring the impedance of the body to applied electric currents of different frequencies. 9, 10 Accumulating evidence suggests that strict BIA-guided fluid management has a beneficial impact on blood pressure, arterial stiffness, left ventricular hypertrophy, and survival in patients undergoing dialysis.
11,12
Thus, we conducted this cross-sectional study to investigate the association between exacerbated ECF status, which occurs with renal function deterioration, and coronary artery calcification (CAC), which is an indicator of cardiovascular disease, in patients at all stages of CKD.
Methods
The authors declare that all supporting data are available within the article and its online supplementary files.
Ethics Statement
This study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the institutional review board at Yonsei University Health System Clinical Trial Center. All patients provided written informed consent before entering the study (institutional review board no. 4-2013-0581 ).
Study Population
The subjects were selected from the CMERC-HI, registration number for study on https://clinicaltrials.gov/NCT02003781 (Cardiovascular and Metabolic Diseases Etiology Research Center-High Risk Cohort) study of the Yonsei University Health System between November 2013 and May 2017. CMERC-HI is an ongoing, nationwide, and prospective cohort study that included patients at a high risk for cardiovascular disease at the Yonsei University Health System, designed to establish an individualized preventive strategy for cardiovascular and cerebrovascular diseases. The following participants were eligible for inclusion in CMERC-HI: patients with a high risk for hypertension, namely, hypertensive patients with an estimated glomerular filtration rate (eGFR) of ≥60 mL/min per 1.73 m 2 and target organ damage, or hypertensive patients with eGFR <60 mL/min per 1.73 m 2 ; diabetic patients with a random urine albumin-to-creatinine ratio of ≥30 mg/g; patients with end-stage renal disease undergoing dialysis; relatives of patients who have acute myocardial infarction and who were younger than 55 years (for men) or 65 years (for women); patients with asymptomatic atherosclerotic cardiovascular disease (abdominal aorta diameter ≥3 cm or ankle-brachial index <0.9, carotid plaque or carotid intima-media thickness ≥0.9 mm, asymptomatic old cerebrovascular accident, or >30% stenosis in at least 1 major coronary artery); patients aged >40 years with rheumatic arthritis and taking methotrexate and steroid; patients with atrial fibrillation with CHA2DS2-VASc score ≥1; and kidney transplant recipients who underwent transplantation >3 months previously. The exclusion criteria were as follows: acute myocardial infarction history (ST-segment-elevation myocardial infarction or non-STsegment-elevation myocardial infarction) or acute coronary syndrome (unstable angina), symptomatic peripheral artery disease, symptomatic heart failure, life expectancy <6 months or severe noncardiovascular disease (metastatic cancer, sepsis, liver cirrhosis), and pregnancy or breastfeeding. From the total of 2367 patients enrolled in the CMERC-HI study, we further excluded patients with end-stage renal disease undergoing dialysis or kidney transplantation, those without BIA data, and those without coronary artery calcium scores (CACSs). Finally, a total of 1741 patients were analyzed for our study (Figure 1 ).
Body Composition and ECF Status Measurement
ECF status was assessed with BIA (InBody 720 Body Composition Analyzer; BioSpace, Seoul, Korea) at the time of enrollment. A direct segmental multifrequency BIA method was used with a tetra-polar 8-point tactile electrode system, with 30 impedance measurements obtained using 6 frequencies. High-frequency current passes through the total body water (TBW), whereas low-frequency current cannot penetrate cell membranes and thus flows exclusively through the extracellular water (ECW). On the basis of a fluid model with these resistances, the ECW, intracellular water, and TBW were
Clinical Perspective
What Is New?
• Extracellular fluid status deteriorated with declining renal function and was independently associated with a high risk of coronary artery calcification in patients with chronic kidney disease.
• Our large-scale study is the first to identify extracellular fluid excess as a nontraditional factor associated with coronary artery calcification in patients at all stages of chronic kidney disease.
What Are the Clinical Implications?
• Extracellular fluid status may be a contributing factor to the development of coronary artery calcification in patients with chronic kidney disease.
• Our study provides a basis for further investigations to determine the direct effect of extracellular fluid status on the pathogenesis of coronary artery calcification.
calculated. According to the concept that excess ECW results in edema, ECF status was defined as the ECW-to-TBW ratio (ECW/TBW), and ECF excess was classified as follows: mild overhydrated state (ECW/TBW 0.390-0.399) and moderate to severe overhydrated state (ECW/TBW ≥0.400) (Biospace Co. Ltd., Seoul, Korea).
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Assessment and Definition of CAC
All examinations were performed with a 320-row computed tomography system (Aquilion ONE; Toshiba Medical Systems, Tokyo, Japan) with subjects in the supine position on a table, and images were acquired during a single breath hold, to allow image reconstruction in a single cardiac phase. Dual scanograms were used for planning the examination and determining the anatomical range. To obtain the CACSs, a nonenhanced prospective ECG-gated scan was performed with the following parameters: rotation time, 275 ms; slice collimation, 0.5 mm; slice width, 3.0 mm; tube voltage, 100 kV; and automatic tube current modulation. Images were analyzed in a core workstation with dedicated software (version 4.4.11.82.3430.Beta; TeraRecon, Foster City, CA). Agatston calcium scores were calculated to quantify the extent of CAC. A total CACS of ≥400 was defined as CAC.
14,15
Clinical and Biochemical Data Collection
Clinical data and laboratory parameters were collected at the time of cohort enrollment. Diabetes mellitus was defined as a history of diabetes mellitus, use of antidiabetic medications, or fasting plasma glucose levels >126 mg/dL; hypertension was defined as a self-reported history of hypertension, a history of antihypertensive medication use, or a blood pressure of 140/ 90 mm Hg or higher at the time of visit; and cardiovascular disease was defined as a composite of coronary occlusive disease, ischemic heart disease, congestive heart failure, atrial fibrillation, atherosclerosis, and cerebrovascular disease. Medications including antihypertensive and antidiabetic drugs and diuretics were investigated based on prescriptions at the time of enrollment. Height, weight, body mass index, and anthropometric data were measured. Moreover, 24-hour ambulatory blood pressure monitoring was performed using a Takeda TM-2430 instrument (A&D Medical, Tokyo, Japan). The pulse pressure measured with 24-hour ambulatory blood pressure monitoring was used in this analysis. Lipid profile components and glucose levels were measured in blood samples obtained after a 12-hour fast. The eGFR was calculated according to the CKD Epidemiology Collaboration equation based on serum creatinine level. 16 The CKD stages were defined on the basis of eGFR.
Statistical Analyses
Continuous variables were expressed as the mean and SD or median with interquartile ranges, and categorical data were presented as counts with percentages. 
Results
Baseline Characteristics
At the time of enrollment, there was a significant increase in ECF excess with deteriorating renal function among subjects at all stages of CKD. When the subjects were divided into 5 groups according to CKD stage, the results showed that the ECF status was exacerbated and the proportion of ECF excess increased with deteriorating renal function. As evident from the box plots in Figure 2A , the increment of ECW/TBW was more pronounced as the CKD stage became more advanced (from stage 1 to stage 5; 0.384 versus 0.385 versus 0.388 versus 0.391 versus 0.392, P for trend <0.001). As CKD progressed, the proportion of patients with ECF excess tended to increase, and the same tendency was observed in patients with mild-to-severe overhydrated status (ECW/TBW ≥0.390) and those with moderate-to-severe overhydrated status (ECW/TBW ≥0.400) ( Figure 2B ). Table 1 lists the characteristics of the 1741 patients according to the quartiles of ECW/TBW. The mean patient age was 60.8 years, and 54.7% patients were men. The median eGFR was 72. Table S1 .
Association of Clinical and Biochemical Variables With ECF Status
In multivariable linear regression to assess the association of ECW/TBW with variables that were significantly correlated with ECW/TBW in univariable linear regression analysis (Table S2) , CACS was independently associated with ECF status after adjusting for multiple confounders. In addition, age, body mass index, hemoglobin level, and albumin level were related to ECW/TBW in multivariable analysis (Table 2 ). Figure 3 ). Significant variables in the univariable analysis (Table S3 ) and mineral parameters such as calcium and phosphate, which are already known risk factors for CAC, were included in the multivariable models. BMI indicates body mass index; CACS, coronary artery calcium score; CI, confidence interval; ECF, extracellular fluid; eGFR, estimated glomerular filtration rate; uACR, urine albumin-tocreatinine ratio. *Adjusted for age; sex; BMI; waist-to-hip ratio; diabetes mellitus; smoking history; log-transformed CACS; pulse pressure; eGFR; serum hemoglobin, total cholesterol, albumin, calcium, phosphate, and chloride levels; and log-transformed urine albumin-to-creatinine ratio. † Log transformed. (Figure 4) . To confirm the impact of ECF status on the predictive power for the presence of CAC, we carried out reclassification analyses. Adding ECW/TBW to the basic clinical model significantly improved NRI (categorical NRI=0.051, P=0.004; continuous NRI=0.571, P<0.001) and IDI (IDI=0.010, P<0.001) ( Table 4 and Table S4 ). This finding suggested that ECF status improved the predictive power for the presence of CAC.
Sensitivity Analyses
For sensitivity analyses, we further analyzed the association between ECF and CACSs as well as the presence of CAC. In univariate and multivariate analyses, ECF status was statistically significantly associated with log-transformed CACSs (model 3 in Table S5 ; per 0.01 increase, b=0.040, 95% CI, 0.019-0.061, P<0.001). Receiver operating characteristic analysis for the presence of coronary artery calcification. *Adjusted for age; sex; waist-to-hip ratio; hypertension; diabetes mellitus; cardiovascular disease; smoking status; pulse pressure; estimated glomerular filtration rate; hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, and phosphate levels; and use of lipid-lowering agents, antithrombotic agents, and phosphate binders ECW/TBW, extracellular water-to-total body water ratio.
In consideration of the possibility that ECF status was exacerbated by cardiac dysfunction rather than renal impairment, we performed sensitivity analysis of 666 patients with NT-proBNP measurements. As with the analysis results thus far, ECF status showed a strong association with CAC (CAC=83 [12.5%], per 0.01 increase, fully adjusted odds ratio 2.178, 95% CI, 1.412-3.361, P<0.001) (Table S6 ).
Subgroup Analyses
We further evaluated the association between ECF status and CAC in subgroups. We divided the whole cohort into 3 groups: hypertension; diabetes mellitus with albuminuria; and cardiovascular disease consisting of asymptomatic peripheral vascular disease, atrial fibrillation, and heart failure. This association remained unaltered in the group with hypertension (CAC=65 [8.8%], per 0.01 increase of ECW/TBW, fully adjusted odds ratio 2.036, 95% CI, 1.271-3.261, P=0.003) and the group with diabetes mellitus with albuminuria (CAC=152 [20.8%], per 0.01 increase, fully adjusted odds ratio 1.867, 95% CI, 1.409-2.4763, P<0.001). In the group with cardiovascular disease, ECF status was also associated with CAC, but not statistically significantly (Table S7) .
We performed additional subgroup analyses. To determine whether the results of this study are maintained regardless of CKD severity, we divided the subjects into 2 categories: early CKD group consisting of patients with CKD stage 1 to 2 and advanced CKD group consisting of patients with CKD 3 to 5. The results according to the severity of CKD were similar to our main outcomes, and the association was stronger in the advanced CKD group (Table S8) . Finally, we conducted another subgroup analysis according to the use of diuretics. Although the use of diuretics was not associated with ECF status in the linear regression analyses (Table S2 ) and there was no interaction effect between diuretics and ECF status (data not shown), it was already known that diuretics affect the ECF status. From the analysis, we found that the results were consistent with our primary analysis and the association was more intensified in the group of diuretics users (Table S9) .
Discussion
In the present study, we investigated for the first time the association of ECF status with CAC. Preferentially, ECF status was exacerbated and the proportions of patients with ECF excess increased as renal function declined in patients at all stages of CKD. Moreover, the exacerbation of ECF status with declining renal function was independently related to CAC. The association maintained its significance after extensive adjustments for confounding factors in the statistical models to evaluate the predictive power of ECF status for CAC, and in the subgroup and sensitivity analyses. The consistent results across a series of analyses indicate that our findings are robust.
CACS is considered an index of the severity of CAC and is associated with an increased risk for coronary heart disease events, even when other risk factors for coronary heart disease are taken into account. The relative risks associated with increasing CACSs are at least as large as those associated with established coronary heart disease risk factors in the general population. 20 Studies of CACSs in patients with CKD are limited. The incidence of CAC and the CACSs in patients with CKD are higher than those in the general population and lower than those in patients undergoing dialysis. 21 The Chronic Renal Insufficiency Cohort study reported a graded relationship between the severity of CKD and CAC (or CACSs). 22 Although there is controversy about whether CAC has a diagnostic or prognostic value for coronary artery disease in patients with CKD, positive results have been reported recently. The studies of Yiu et al 23 and
Haydar et al 24 showed that CACSs predict coronary artery disease in patients with CKD and in the general population, and Russo et al 25 found that patients with CACS >100 had a greater incidence of cardiac events than patients with CACS ≤100, suggesting that CAC defined as CACSs is an independent predictor of cardiovascular disease in patients with CKD. The possible explanation for why ECF excess causes arterial calcification in patients with CKD may be derived from the mechanical biology or mechanotransduction of vascular cells. In the presence of ECF excess, urinary excretion of sodium and fluid is increased through a negative feedback mechanism to maintain fluid homeostasis. However, if renal function is impaired, urinary excretion of sodium and fluid is reduced and the intrarenal renin-angiotensin-aldosterone system is triggered, leading to persistent and exacerbated ECF excess. 26, 27 This persistent ECF excess results in pathologic mechanical stimuli on vascular endothelial and smooth muscle cells (VSMCs). In endothelial cells, the biological response of this circumferential stretch promotes the release of angiotensin II and the activation of angiotensin II receptor 1, thereby enhancing superoxide production and reducing the bioavailability of nitric oxide. 28, 29 This results in low, oscillating, or reversing shear stress, which in turn leads to atherosclerosis and vascular calcification. 30, 31 VSMCs sense the disturbed wall shear stress and pressure distension caused by intravascular and interstitial fluid overload through membrane mechanoreceptors, and activate the signaling pathways such as small guanosine triphosphatase related to Ras A (RhoA)/Rho-associated protein kinase, mitogen-activated protein kinase, phosphatidylinositol-3-kinase/protein kinase B, and extracellular signal-regulated kinase. [32] [33] [34] These signaling pathways induce the proliferation, migration, apoptosis, and osteoblastic differentiation of VSMCs, and altered VSMCs play a major role in vascular calcification. 35, 36 Recent studies have shown that high shear stress induces apoptosis of VSMCs through nitric oxide released by endothelial cells, 37 and low shear stress upregulates the proliferation and migration of VSMCs via platelet-derived growth factor and transforming growth factor secreted by endothelial cells. 38 Therefore, ECF excess may also be involved in vascular calcification through the cross-talk between endothelial cells and VSMCs. In addition to mechanical stimuli, ECF excess can contribute to vascular calcification through inflammation and oxidation. Several experimental and clinical studies have reported that inflammatory biomarkers such as tumor necrosis factor-a, IL-6, vascular adhesion molecule-1, macrophage, and thrombomodulin were systemically or locally increased in the presence of ECF excess. 39, 40 ECF excess directly induces a phenotype change in VSCMs and indirectly induces oxidative stress, which increases the production of bone morphogenetic protein 2 and endothelial cell-derived microparticles in endothelial cells, thereby enhancing the osteogenic signal acting on VSMCs. [41] [42] [43] Among the causes of vascular calcification in patients with impaired renal function, abnormalities in mineral parameters such as calcium and phosphate are a major concern. However, in this study, no relationship was found between phosphate and calcium levels and the presence of CAC. This association is probably more evident in patients undergoing dialysis than in patients with CKD. There are fewer reports on patients with chronic renal failure, and the results are contradictory. Some studies have reported that calcium, phosphate, and parathyroid hormone, as well as dialysis, promote CAC; however, other studies failed to demonstrate such relationships. 44 In this study, although the levels of calcium and phosphate tended to deteriorate with the progression of renal failure, they were in the normal range suggested by clinical guidelines, 45, 46 even in patients with advanced CKD (Table S1) , and we failed to identify the association between mineral parameters and the presence of CAC (data not shown). Despite some studies showing that phosphate level increases in CAC within the normal range, 47 the Kidney Disease: Improving Global Outcomes and Kidney Disease Outcomes Quality Initiative guidelines do not recommend phosphate lowering in patients with CAC in the normal range. 45, 46 Further research is needed to establish strong evidence. This study has distinct strengths. This is the first study to identify ECF excess as a nontraditional factor associated with CAC in patients at all stages of CKD. In addition, this study was conducted in a prospective manner and with a large-scale cohort including 1741 patients. All measurements, including ECF status and CACS, were taken in almost all patients and were performed by a well-trained evaluator using a standardized protocol in the same machine for each metric. Therefore, these accurate measurements made our findings highly reliable. This study also has some important limitations. First, because of its cross-sectional design, we could not determine the causative relationship of ECF excess to CAC. Therefore, prospective and longitudinal studies are needed to determine whether ECF excess predicts future CAC. In addition, we expect to be able to confirm this issue upon completion of the ongoing CMERC-HI study. We also look forward to studying whether ECF status can predict the incidence of CAC in patients without CAC at study enrollment. Second, this study cannot be generalized to the whole CKD population because we used data from a cohort comprising patients at a high risk for cardiovascular disease. However, we cautiously assumed that our findings would be maintained in other CKD populations because we found consistent results in all subgroup and sensitivity analyses. Third, in this study, we used BIA to assess volume status and did not directly measure body water. The criterion standard for assessing fluid status is the tracer dilution technique. However, it is difficult to use in clinical practice and it is known to correlate well with BIA. 48 Furthermore, the reproducibility and reliability of our multifrequency BIA method have already been verified in previous studies. 49, 50 Fourth, there are unmeasured confounding factors that may alter the relationship between ECW/TBW and CAC. We could not measure the degree of sodium intake associated with ECF status and the levels of parathyroid hormone or vitamin D, known to affect vascular calcification, 51 at the time of enrollment. Fifth, the mechanism by which ECF excess contributes to vascular calcification is not proven by our own experiments. We have carefully reviewed as much of the literature as possible to make up for these limitations, and we expect further studies to be done.
In conclusion, ECF status, which is affected by renal function, is significantly and independently associated with CAC at all stages of CKD without dialysis. The present study suggests that ECF status may be one of the contributing factors to the development of CAC in patients with CKD and provides a basis for further investigations to determine the direct effect of ECF status on the pathogenesis of CAC.
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